2Chen KR, Carlson JA. Clinical approach to cutaneous vasculitis. Am J Clin Dermatol 2008 ; 9 : 71 - 92.
3Tai YJ, Chong AH, Wialliams RA, et al. Retrospective analysis of adult patients with cutaneous leukocytoclastic vasculitis. Australas J Dermatol 2006;47(2):92- 96.
4Spangenberg HC, Blum HE. Vasculitis and liver disease. Schweiz Rundsch Med Prax 2006 ;95:1557- 1562.
5Surmali Onay O, Baskin E, Ozcay F, et al. Successsful treatment of hepatitis B - associated leukocytoclastic vasculitis with lamivudine treatment in a child patient. Rheumatol Int 2007;27 (9) :869 - 872.
6Solans- Laque R, Bosch- Gil JA, Perez - Bocanegra C, et al. Paraneoplastic vasculitis in patients with solid tumors: report of 15 cases. J Reumatol 2008 ; 35 : 294 - 304.
3Ibanez C,Montoro-Ronsano JB.Intravenous immunoglobulin preparations and autoimmune disorders:mechanisms of action.Curr Pharm Biotechnol,2003,4:239-247.
4Mydlarski PR,Mittmann N,Shear NH.Intravenous immunoglobulin:use in dermatology.Skin Therapy Lett,2004,9:1-6.
5Ahmed AR,Dahl MV.Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases.Arch Dermatol,2003,139:1051-1059.
7Viard I,WehrliP,Bullani R.et al.Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin.Science 1998;282:490-493.
8Bachot N,Revui J,Roujeau JC.Intravenous immunoglobulin treatment for Stenvens-Johnson syndrome and toxic epidermal necrolysis:a prospective noncompamtlve study showing no benefit on mortality or progression.Arch Dermatol 2003;139:33-36.
9Rago JV,Vath GM,Bohach GA,et al.Mutational analysis of the superantigen staphylococal extoliative toxic A(ETA).Immunol 2000;164:2207-2213.
